Lineage Cell Therapeutics, Inc. (TLV:LCTX)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
298.50
+3.40 (1.15%)
Jun 18, 2025, 5:24 PM IDT

Lineage Cell Therapeutics Revenue

Lineage Cell Therapeutics had revenue of $1.50M USD in the quarter ending March 31, 2025, with 4.02% growth. This brings the company's revenue in the last twelve months to $9.56M, up 19.42% year-over-year. In the year 2024, Lineage Cell Therapeutics had annual revenue of $9.50M with 6.19% growth.

Revenue (ttm)
$9.56M
Revenue Growth
+19.42%
P/S Ratio
20.38
Revenue / Employee
$124.12K
Employees
77
Market Cap
725.21M ILS

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20249.50M554.00K6.19%
Dec 31, 20238.95M-5.76M-39.16%
Dec 31, 202214.70M10.36M238.70%
Dec 31, 20214.34M2.52M137.73%
Dec 31, 20201.83M-1.69M-48.05%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Teva Pharmaceutical Industries 61.87B
Danel (Adir Yeoshua) 2.81B
Kamada 622.70M
Bait Bakfar 104.50M
BrainsWay 161.81M
Novolog (Pharm-Up 1966) 2.07B
SofWave Medical 235.09M
Ilex Medical 922.08M
Revenue Rankings